Axplora Expands Commercial Payload Production at Le Mans

Axplora Expands Commercial Payload Production at Le Mans

Germany-based Axplora, which is involved in API small molecule and ADC manufacturing, launched a payload manufacturing workshop at its Le Mans site in France. The new GMP workshop is currently equipped with three Hastelloy reactors, and can accommodate a fourth, offering a production range of 30 to 200 L. Additionally, a dedicated Hastelloy filter dryer focuses on high-level containment and safety.

Producing batches up to 1.5 kg, this facility is engineered to support the growing demand for next-generation payload families that are driving innovation in oncology therapies such as Auristatins, according to company officials.

The expansion of Axplora’s Le Mans facility features six dedicated ADC workshops, split across two for clinical payload-linker production, two for commercial payloads, and two for bioconjugation. This integrated approach streamlines project management, enabling Axplora to support ADC development at every stage and scale up production to commercial supply manufacturing,” stated Arul Ramadurai, chief commercial officer.

With over 20 years of expertise in cGMP ADC development and manufacturing, and with more than 250 cGMP batches produced, the Le Mans site is also home to four purification lines ranging from small to large scale. These lines leverage high-performance chromatography for producing efficient, high-quality cytotoxics.

Clients also benefit from Axplora’s best-in-class payload-linker development laboratories, bioconjugation suites, and drug product release testing, enabling seamless transition from early clinical phases to commercial production—all with a single team of experts guiding the process to de-risk supply chains, continued Ramadurai.

“This expansion is a bold step forward in our mission to support clients at every stage of ADC development and manufacturing,” said Ramadurai. “By combining payload manufacturing with our expertise in purification and bioconjugation, we’re enabling pharmaceutical innovators to accelerate drug development and deliver transformative treatments to patients faster.”

Share:
error: Content is protected !!